Which Is Better Cox-2 Inhibitor Or Arcoxia For Knee Pain?
A new study on the COX-2 inhibitor Arcoxia is intensifying worries about the drug's safety. Though researchers found that the new drug had similar rates of cardiovascular risks as diclofenac, a common arthritis medication, their data also showed that Arcoxia patients had significantly higher rates of high blood pressure and fluid retention. Though Arcoxia has not yet been approved for use in the United States, it is currently on the market in 62 countries.
Read moreMore information on "Which Is Better Cox-2 Inhibitor Or Arcoxia For Knee Pain?"
From Our Experts
Merck Study Finds Similarities with COX-2 inhibitor & NSAID drugs
Merck, the manufacturer of Vioxx recently announced that preliminary analyses of its MEDAL (Multinational Etoricoxib and Diclofenac... Read more »
Cox-2 Inhibitors Revisited, Again
A couple of months back I wrote a blog discussing the concerns I and many others have regarding the return of severe gastrointestinal side... Read more »
Update from the American College of Rheumatology: Cox-2 Inhibitors...
When Cox-2 inhibitors first came on the market there was almost euphoria: Finally, those patients with chronic pain and in need of... Read more »
Celebrex and COX-2 Inhibitors vs. Anti-Inflammatories
A couple of months back I wrote a post discussing the concerns I and many others have regarding the return of severe gastrointestinal side... Read more »
FDA Advisory Panel to Evaluate Arcoxia, a Vioxx Replacement
On Thursday, April 12 an FDA advisory panel will discuss whether or not to recommend that the FDA approve Merck & Co’s... Read more »
From Our Sources
Arcoxia safety study gives mixed results
An advisory panel to the U.S. Food and Drug Administration has found mixed results about the safety of the new COX-2 inhibitor Arcoxia. In a recent... Read more »
Data on new COX-2 painkiller set to be released
Results from a large study on Merck's new COX-2 inhibitor drug, Arcoxia, are about to be released. Many doctors and patients are awaiting the results... Read more »
FDA advisory panel rejects new COX-2 painkiller
A panel of experts that advises the U.S. Food and Drug Administration (FDA) has recommended that the new COX-2 inhibitor Arcoxia should not be... Read more »
FDA rejects Arcoxia
The U.S. Food and Drug Administration (FDA) has rejected drugmaker Merck's request to sell the COX-2 inhibitor Arcoxia in the United States. Arcoxia... Read more »
Study points to cause of COX-2's heart risks
Scientists believe they've discovered what causes COX-2 inhibitors such as Vioxx and Celebrex to boost users' heart risks. Researchers working with... Read more »
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
